Background: A population of regulatory T cells (Treg), which reside within thymic nurse cell complexes, express adiponectin and abrogate breast cancer development in transgenic mice. In this study, we examined whether adiponectin‐expressing Treg could impair triple‐negative breast cancer, which is defined by a lack of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor‐2.Methods: CD4‐ and CD25‐positive cells were sorted from cultured T lymphocytes of a previously characterized experimental thymic tumor model composed of thymic nurse cells and abundant lymphoid stroma. These sorted cells were examined for FOXP3 and adiponectin immunoreactivity and subsequently exposed to triple‐negative breast cancer MDA‐MB‐157 and ‐231 cells.Results: Adiponectin‐expressing Treg were obtained by CD4‐ and CD25‐positive sorting and cell death was induced in triple‐negative breast cancer cells through the cell‐in‐cell phenomenon.Conclusions: Adiponectin‐expressing Treg may be candidates for adoptive cell therapy against triple‐negative breast cancer.
Malignant pleural mesothelioma (MPM) develops primarily from asbestos exposures and has a poor prognosis. In this study, The Cancer Genome Atlas was used to perform a comprehensive survival analysis, which identified the CHST4 gene as a potential predictor of favorable overall survival for patients with MPM. An enrichment analysis of favorable prognostic genes, including CHST4, showed immune-related ontological terms, whereas an analysis of unfavorable prognostic genes indicated cell-cycle-related terms. CHST4 mRNA expression in MPM was significantly correlated with Bindea immune-gene signatures. To validate the relationship between CHST4 expression and prognosis, we performed an immunohistochemical analysis of CHST4 protein expression in 23 surgical specimens from surgically treated patients with MPM who achieved macroscopic complete resection. The score calculated from the proportion and intensity staining was used to compare the intensity of CHST4 gene expression, which showed that CHST4 expression was stronger in patients with a better postoperative prognosis. The median overall postoperative survival was 107.8 months in the high-expression-score group and 38.0 months in the low-score group (p = 0.044, log-rank test). Survival after recurrence was also significantly improved by CHST4 expression. These results suggest that CHST4 is useful as a prognostic biomarker in MPM.
11 March 2024 in Pathology - Research and Practice
Background: In our previous study, we identified a population of adiponectin expressing regulatory T cells (Tregs) residing within thymic nurse cell complexes, which were capable of inhibiting the development of breast cancer in vitro. Triple‐negative breast cancer (TNBC) with no proper treatment at present is characterized by the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor‐2. In this study, we aimed to investigate the potential of a cultured T cell fraction comprising adiponectin‐expressing Tregs, referred to as A‐TregTF (adiponectin‐expressing Treg‐containing T cell fraction), in inhibiting the progression of TNBC in vivo.Methods: The efficacy of a spontaneously expanding T cell fraction comprising adiponectin‐expressing Treg in inhibiting tumor growth was analyzed in a murine orthotopic 4 T1‐Luc TNBC model.Results: The treatment with T cell fraction containing adiponectin‐expressing Tregs significantly inhibited the growth and metastasis of orthotopically transplanted 4 T1‐Luc tumor cells. Histopathological examination further revealed that the adiponectin‐expressing Tregs infiltrated the tumor tissue via a cell‐in‐cell mechanism and were found to be specifically localized around the necrotic areas.Conclusions: Based on our findings, the T cell fraction comprising adiponectin‐expressing Tregs, represents a potential candidate for adoptive cell therapy against TNBC.
25 August 2026 in Cancer Treatment and Research Communications
Lysyl oxidase-like 1 (LOXL1) is believed to play pleiotropic roles in various cancers, including modulation of tumor-immune interactions. However, its clinicopathological significance in lung carcinogenesis remains poorly defined. In this study, we evaluated LOXL1 expression in non-small cell lung cancer (NSCLC) and assessed its clinicopathological correlates. LOXL1 expression was analyzed in surgically resected NSCLC tissue specimens obtained from 88 patients. In this cohort, 59 tumors exhibited high LOXL1 immunoreactivity and 29 exhibited low immunoreactivity. LOXL1-high immunoreactivity was significantly associated with increased CD8+ T-cell infiltration, reduced lymphatic invasion, reduced lymph node metastasis, and earlier pathological stage. Kaplan-Meier analysis demonstrated that patients with LOXL1-high immunoreactivity had significantly longer disease-specific and relapse-free survival (log-rank test, P = 0.014 and 0.023, respectively). Collectively, these findings suggest that LOXL1 expression is a potential clinicopathological biomarker in NSCLC.
Epithelial‐mesenchymal transition (EMT) plays a crucial role in carcinogenesis, including mesothelioma. D‐Meso‐Sonobe is a deciduoid‐type mesothelioma cell line with morphological features similar to those of epithelioid cells. Here, we report that D‐Meso‐Sonobe cells exhibit spindle cell mesenchymal features under continuous confluent culture conditions. The spindle cell mesenchymal D‐Meso‐Sonobe expresses zinc finger E‐box‐binding homeobox 1 (Zeb1), which is a master regulator of EMT in the nucleus. Xenoplanted D‐Meso‐Sonobe cells expressed nuclear Zeb1 and yes‐associated protein at the cancer invasion front and focally expressed integrin subunit alpha V and actin alpha 2, which are molecular phenotypes acquired by EMT in mesothelioma. Subsequent RNA sequencing revealed that lysyl oxidase like 1 (LOXL1) was more highly expressed in cultured spindle mesenchymal D‐Meso‐Sonobe cells than in epithelioid cells. LOXL1 immunoreactivity was observed at the invasive front of xenoplanted D‐Meso‐Sonobe cells. The epithelial‐mesenchymal plasticity of D‐Meso‐Sonobe cells may be applicable for the development of candidate molecular agents targeting EMT in mesothelioma.